Trial profile. Best response by cycle 6 was the primary end point of the trial. Patients with stable disease (SD) or better could remain in the study and receive a maximum of 17 cycles of treatment. Best response is indicated in parentheses. CR, complete response; I/T/DIN, irinotecan, temozolomide, and dintuximab; PD, progressive disease; PR, partial response.